Boundless Bio director granted 32,000 stock options

Boundless Bio director Nancy Whiting received a grant of stock options for 32,000 shares of Common Stock at an exercise price of $1.40 per share.

Rhea-AI Filing Summary

Boundless Bio director Nancy Whiting received a grant of stock options for 32,000 shares of Common Stock at an exercise price of $1.40 per share. The options vest in substantially equal monthly installments over 12 months after June 15, 2026, or in full at the next annual stockholder meeting before June 15, 2027, if earlier, contingent on continued board service.

Insider Trade Summary

Grant/Award: 32,000 shares

Grant/Award 1 txn

Insider Whiting Nancy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	32,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 32,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.

Key Figures

Option grant size: 32,000 shares Exercise price: $1.40 per share Shares after transaction: 32,000 options +2 more

5 metrics

Option grant size 32,000 shares Stock Option (right to buy) granted to director

Exercise price $1.40 per share Conversion or exercise price of stock options

Shares after transaction 32,000 options Total derivative securities following transaction

Expiration date June 14, 2036 Option expiration for stock option grant

Vesting period 12 monthly installments Over 12 months following June 15, 2026

Key Terms

Stock Option (right to buy), Common Stock, vest, board of directors

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest financial

"The stock option shall vest in substantially equal monthly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

board of directors financial

"subject to the reporting person's continuing service on the issuer's board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Boundless Bio (BOLD) director Nancy Whiting report on this Form 4?

Nancy Whiting reported receiving a grant of stock options for 32,000 shares of Boundless Bio Common Stock. These options were granted as compensation for board service and give her the right to buy shares at a fixed $1.40 exercise price before expiration.

How many Boundless Bio (BOLD) shares are covered by the new stock options?

The stock option grant covers 32,000 shares of Boundless Bio Common Stock. This means Whiting can purchase up to 32,000 shares at the preset $1.40 exercise price if and when the options vest and she chooses to exercise them.

What is the exercise price and expiration date of Nancy Whiting’s Boundless Bio options?

The stock options have an exercise price of $1.40 per share and expire on June 14, 2036. Whiting may exercise vested options any time before that expiration date, subject to the plan and any applicable company policies.

How do the Boundless Bio (BOLD) stock options granted to Nancy Whiting vest?

The options vest in substantially equal monthly installments over the 12 months following June 15, 2026. If Boundless Bio holds its next annual stockholder meeting before June 15, 2027, any remaining unvested portion vests on that meeting date, assuming continued board service.

Is this Boundless Bio Form 4 transaction a market purchase or sale of shares?

No, this Form 4 reflects a compensation-related grant of stock options, not an open-market trade. Whiting did not buy or sell shares in the market; she received the right to purchase shares later at $1.40, subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 07:40 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Whiting Nancy

(Last) (First) (Middle)

C/O BOUNDLESS BIO, INC.

11099 NORTH TORREY PINES RD., STE 150

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Boundless Bio, Inc. [ BOLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.4	06/15/2026		A		32,000		(1)	06/14/2036	Common Stock	32,000	$0	32,000	D

Explanation of Responses:

1. The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.

	/s/ Jessica Oien, Attorney-in-Fact for Nancy Whiting	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)